期刊文献+

BAFF启动子-871C/T基因多态性在ITP患者中的意义 被引量:5

Significance of B Cell Activating Factor of TNF Family Promoter Polymorphisms in Patients with Immune Thrombocytopenic Purpura
暂未订购
导出
摘要 本研究通过检测B细胞活化因子(BAFF)启动子-871C/T基因多态性在特发性血小板减少性紫癜(ITP)患者中的分布情况,探讨其与ITP发病的相关性,并研究ITP患者初诊时血小板计数与BAFF-871C/T基因型的关系。选择133例ITP患者和117例健康对照者,应用等位基因特异性PCR(ASP?PCR)及琼脂糖凝胶电泳检测BAFF-871C/T多态性,判定各研究对象的基因型,并统计各基因型及等位基因的频率。结果表明:C/C、C/T、T/T3种基因型分布在ITP组分别为33.1%、42.1%、24.8%,对照组分别为55.6%、33.3%、11.1%。T等位基因频率在ITP组为45.9%、对照组为27.4%,差异均有统计学意义(p<0.05)。ITP组T等位基因频率高于对照组。各基因型间血小板计数无统计学差异(p>0.05)。结论:BAFF启动子-871C/T多态性可能与ITP的发病有相关性,但各基因型之间患者初诊时血小板计数没有差别,不能作为病情严重程度的评价指标。 The study was aimed to examine the B cell activating factor promoter polymorphism of the TNF family (BAFF)-871 C/T in patients with immune thrombocytopenic purpura (ITP) and to explore its correlation with ITP and the relationship between the blood platelet count of newly diagnosed patients with ITP and genotypes of BAFF -871 C/T polymorphisms. Alleles specific polymerase chain reaction (ASP-PCR) and agarose gel electrophoresis were used to identify polymorphisms -871 C/T of BAFF promotor in 133 ITP patients and 117 healthy controls, and determine the genotype of subjects. Meantime, the frequency of genotype and alleles were analyzed. The results indicated that out of 133 patients with ITP, 33.1% patients exhibited C/C, 42.1% patients were heterozygous C/T, and 24.8% patients were homozygous T/T. The corresponding frequencies in 117 healthy controls were 55.6% C/C, 33.3% C/T and 11. 1% T/T. The allele frequency of T in ITP patients and healthy controls were 45.9% and 27.4% respectively. There was significant difference in the BAFF-871 C/T genotypic frequency between the ITP patients and healthy controls(p 〈 0.05). The allele frequency of T in ITP patients was higher than that in healthy controls. There was no significant difference in the blood platelet counts between the various genotype (p 〉 0.05 ). It is concluded that the polymorphism - 871 C/T of BAFF promoter is correlated with the pathogenesis of ITP. However, there is no significant difference in blood platelet counts between the various genotype, so the polymorphism -871 C/T of BAFF promoter can not be referred as the analysis index for evaluating the severity of ITP.
出处 《中国实验血液学杂志》 CAS CSCD 2010年第3期690-693,共4页 Journal of Experimental Hematology
基金 2008年国家公益性科研专项基金 编号200802031
关键词 特发性血小板减少性紫癜 B细胞活化因子 基因多态性 immune thrombocytopenic purpura BAFF gene polymorphisms
  • 相关文献

参考文献12

  • 1Mackay F, Schneider P, Rennert P, et al. BAFF and APRIL: a tutorial on B-cell survival. Annu Rev Immunol, 2003;21:231 - 264.
  • 2Kawasaki A, Tsuchiya N, Fukazawa T, et al. Analysis on the association of human BLYS ( BAFF, TNFSF13B ) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun, 2002 ;3 ( 7 ) : 424 - 429.
  • 3Emmerich F, Bal G, Barakat A, et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol, 2007; 136 (2) : 309 -314.
  • 4Mackay F, Browning JL. BAFF: A fundamental survival factor for B cells. Nat Rev Immunol,2002 ;2(7) :465 -475.
  • 5Moore PA, Belvedere O, Orr A, et al. BlyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science, 1999 ;285 ( 5425 ) :260 - 263.
  • 6O'Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med, 2004;199(1) :91 -98.
  • 7Enzler T, Bonizzi G, Silverman GJ, et al. Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 2006;25 (3) :403 -415.
  • 8Cheema GS, Roschke V, Hilbert DM, et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immunebased rheumatic diseases. Arthritis Rheum, 2001 ; 44 ( 6 ) : 1313 - 1319.
  • 9Zhu XJ, Shi Y, Peng J, et al. The effects of BAFF and BAFF-R- Fc fusion protein in immune thrombocytopenia. Blood,2009:114 (26) :5362-5367.
  • 10Novak AJ, Grote DM, Ziesmer SC, et al. Elevated serum B- lymphocyte stimulator levels in patients with familial lympho- proliferative disorders. J Clin Oncol, 2006;24(6) : 983 -987.

同被引文献55

  • 1陆进明,李志,陈兰芳,宣丹,徐亮.类风湿关节炎中B细胞活化因子的研究[J].中国现代药物应用,2007,1(9):11-12. 被引量:2
  • 2Morimoto S,Nakano S,Watanabe T,et al.Expression of B-cell activating factor of the tumor necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus:the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.Rheumatology(Oxford),2007,46(7):1083-1086.
  • 3Ding C.Belimumab,and anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases.Expert Opina Ther,2008,8 (11):1805-1814.
  • 4Mariette X,Roux S,Zhang J,et al.The level of BLyS (BAFF)correlates with the titre of autoantibodies in human Sjogren's syndrome.Ann Rheum Dis,2003,62(2):168-171.
  • 5Emmerich F,Bal G,Barakat A,et al.High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura.Br J Haematol,2007,136(2):309-314.
  • 6Zhou Z,Chen Z,Li H,et al.BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura.Autoimmunity,2009,42(2):112-119.
  • 7Zhu XJ,Shi Y,Sun JZ,et al.High-dose dexamethasone inhibits BAFF expression in patients with immune thromobocytopenia.J Clin Immunol,2009,29 (5):603-610.
  • 8Reyes LI,Leon F,Gonzclez P,et al.Dexama thasone inhibits BAFF expression in fibroblast-like synovicytes from patients with rheumatoid arthritis.Cytokine,2008,42 (2):170-178.
  • 9Lavie F,Miceli Richard C,Ittah M,et al.Increase of B cell activating factor of the TNF family (BAFF) after rituximab treatment:insights into a new regulating system of BAFF production.Ann Rheum Dis,2007,66(5):700-702.
  • 10Ragheb S,Lisak R,Lewis R,et al.A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis.Arch Neurol,2008,65(10):1358-1362.

引证文献5

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部